SUMMARY The acute effects of felodipine on left ventricular function and haemodynamics were studied in 11 patients with coronary artery disease. To block reflex sympathetic activation due to peripheral vasodilatation and to avoid effects secondary to changes in heart rate all patients received a standard regimen of beta adrenoceptor blockade and all measurements were made during sinus rhythm and right atrial pacing. At 30 minutes after an oral dose (0.075 mg/kg in solution) felodipine plasma concentration were 16-4 (3-5) nmol/l. A significant fall in systemic vascular resistance (30%) and increase in cardiac index (30%) occurred, whereas pulmonary vascular resistance was unchanged. Felodipine increased left ventricular ejection fraction and mean velocity of circumferential fibre shortening but had no effect on derivates of left ventricular pressure (dP/dt or dP/dt P-1) during sinus rhythm or pacing. Thus at the dosage used felodipine was a potent dilator of systemic arterioles but had no direct effect on left ventricular function.
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Felodipine is a new dihydropyridine compound, which has been claimed (in vitro) to be a potent vasodilator with less cardiodepressive effect than other calcium antagonists.' Its mechanism of action in relaxing vascular smooth muscle is unclear, although it has been suggested that it inhibits the activation, by calcium ions, of intracellular calmodulin2 and only at high concentration does it act as a slow calcium channel blocker. A non-invasive study3 of young healthy men confirmed its action as a vasodilator in man; there are, however, no direct measurements available of its effect on left ventricular function. In this study therefore we measured the systemic and left ventricular haemodynamic effects of felodipine in patients undergoing cardiac catheterisation for investigation of chest pain. We and others45 have previously shown that control of heart rate and blockade of reflex sympathetic activation is essential to avoid masking direct negative inotropic actions of peripheral vasodilators.6-8 For this reason measurements were carried out at rest and during atrial pacing in patients receiving beta blocking agents. 
Patients and methods
Eleven men aged 34-62 (mean 49.6) years were entered into the study. All patients had classical angina pectoris and positive exercise tests (Bruce protocol) and were about to undergo cardiac catheterisation. Coronary arteriography at the end of each study showed that all had coronary artery disease (four single vessel disease, six two vessel disease, and one left main stem disease). Seven of the 11 had had a previous myocardial infarct (more than three months before the study), but none had congestive heart failure, cardiac conduction abnormalities, valvular heart disease, or biochemical evidence of hepatic or renal disease. Medical treatment at entry to the stdy consisted of a beta adrenoreceptor blocker in nine patients, long acting oral nitrate in eight, calcium antagonists in four, and other vasodilators in two. Nitrates, vasodilators, and beta adrenoceptor blockers were discontinued for at least 24 hours before the study, and to standardise beta adrenoreceptor blocking treatment all patients received atenolol 100 mg six hourly for the same period.
The patients were studied after an overnight fast and premedication with diazepam (10 mg) orally. Heart rate was measured from electrocardiograms (mean of six beats). A Swan-Ganz thermodilution catheter was positioned in the pulmonary artery for 432 pressure recording, blood sampling, and estimation of cardiac output (mean of three readings). A bipolar pacing electrode was positioned in the right atrium. Arterial pressure was recorded from the sidearm of a sheath positioned in the femoral artery. A pressure tip catheter (Millar Instruments) was passed via the sheath to the left ventricle for high fidelity recordings; derivatives of left ventricular pressure (dP/dt and dP/dt P-') were obtained using analogue circuitry (Siemens). Stroke volume, ejection fraction,9 and mean velocity of circumferential fibre shortening10
were derived from left ventricular angiograms.
Control haemodynamic measurements were taken during sinus rhythm and during right atrial pacing at 100 beats/min, and a baseline left ventricular angiogram was then performed (40 ml Hexabrix at 12 ml/s) during pacing. Repeat measurements including left ventriculography were obtained 30 minutes after felodipine 0-075 mg/kg had been given orally. Blood samples for the estimation of plasma felodipine concentrations were taken during the baseline recordings, at 10, 20, and 30 minutes after the oral dose, and after the second left ventricular angiogram. To assess the haemodynamic effects of the contrast material used separate studies were carried out in a further seven patients who underwent the initial left ventricular angiogram but received no drug, after which haemodynamic measurements were made in the usual way. Results are expressed as mean (SE) and were analysed using Student's t test, a probability value of 0.05 being taken to indicate statistical significance.
Results

HAEMODYNAMIC EFFECTS OF CONTRAST INJECTION
The haemodynamic changes in seven patients after left ventriculography using 45 ml of Hexabrix (May and Baker) who received no felodipine were minor. Heart rate was increased by 6% and 5% at 10 and 20 minutes respectively, mean pulmonary pressure was increased by 10% at 20 minutes, and left ventricular dP/dt P-I was increased by 5% at 20 minutes (p < 0-05 in each case). No significant changes were observed at 30 minutes. . In contrast, pulmonary vascular resistance was of systemic arterioles producing a significant reducreduced by 11% during pacing and by 1.3% during tion in systemic vascular resistance and a significant sinus rhythm, and neither was statistically significant. increase in cardiac index in a dose which had no effect on left ventricular peak dP/dt or peak dP/dt P-I.
INDICES OF LEFT VENTRICULAR FUNCTION
Haemodynamic effects of the initial injection of conIncreasing heart rate by atrial pacing produced a trast material can be excluded since no significant significant increase in left ventricular dP/dt and effects were detectable 30 minutes later. The dosage dP/dt P-before (180/o and 2r/o respectively) and after of felodipine used appears to have little effect on pul-(13% and 21% respectively) the administration of monary arterioles, there being no significant change in felodipine. Felodipine had no effect on these pulmonary vascular resistance. During sinus rhythm isovolumic indices of left ventricular function during felodipine produced a small but significant increase in sinus rhythm or during atrial pacing. In contrast ejec-heart rate despite concurrent beta adrenoreceptor tion fraction, stroke volume, and mean velocity of blockade. There is no evidence that felodipine has a circumferential fibre shortening were substantially direct positive chronotropic action on the heart. The increased (13%, 80/o, and 19% respectively) at 30 dose of atenolol used was high, and the low initial minutes, although these changes did not reach statis-heart rates suggest that indeed substantial beta tical significance.
adrenoreceptor blockade was present. The small rate and sympathetic activation in vivo, so that when heart rate and sympathetic activation were controlled dP/dt and dP/dt P-I were reduced.45 The increase in stroke volume, ejection fraction, and mean velocity circumferential fibre shortening in the present study can be explained by the reduction in systemic arteriolar resistance.
These studies confirm that felodipine is a potent dilator of systemic arterioles with relatively little effect on the pulmonary circulation or systemic veins. The dose used in the present study produced a pronounced fall in systemic vascular resistance with no detectable effect on myocardial performance. This suggests that the drug is highly selective for smooth muscle and that it is likely to be a useful vasodilator for the treatment of cardiac failure or hypertension associated with myocardial damage.
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